Tumor Suppressor MicroRNA-493 Decreases Cell Motility and Migration Ability in Human Bladder Cancer Cells by Downregulating RhoC and FZD4

Koji Ueno¹, Hiroshi Hirata¹, Shahana Majid¹, Soichiro Yamamura¹, Varahram Shahryari¹, Z. Laura Tabatabai², Yuji Hinoda³, and Rajvir Dahiya¹

Abstract

The purpose of this study was to identify new tumor suppressor microRNAs (miRNA; miR) in bladder cancer, conduct functional analysis of their suppressive role, and identify their specific target genes. To explore tumor suppressor miRs in bladder cancer, miR microarray was conducted using SV-HUC-1, T24, J82, and TCCSUP cells. Expression of miR-493 in bladder cancer (T24, J82, and TCCSUP) cells was downregulated compared with normal SV-HUC-1 cells. Also, the expression of miR-493 was significantly lower in bladder cancer tissues than in their corresponding noncancerous tissues. Transfection of miR-493 into T24 or J82 cells decreased their cell growth and migration abilities. On the basis of this result, to identify potential miR-493 target genes, we used target scan algorithms to identify target oncogenes related to invasion and migration. miR-493 decreased 3'-untranslated region luciferase activity and protein expression of FZD4 and RhoC. miR-493 also decreased binding of RhoC and Rock-1. miR-493 is a new tumor suppressor miRNA in bladder cancer and inhibits cell motility through downregulation of RhoC and FZD4.

Introduction

Bladder cancer is the ninth leading cause of death among men, accounting for 3% of total cancer (1). The most common histologic type of bladder cancer is urothelial carcinoma, which was formerly known as transitional cell carcinoma (2). Approximately 75% of patients are nonmuscle invasive urothelial carcinoma (pTa, pTis, pT1) and have a 5-year survival rate between 88% and 98% (3). The common treatment for these patients is endoscopic resection (2, 4). Patients with muscle invasive urothelial carcinoma are usually treated with radical cystectomy or chemoradiotherapy (2, 5). However, half of the patients with muscle-invasive urothelial carcinoma develop subsequent metastatic disease after the first aggressive treatment (2, 6). Previous studies have identified several potential molecular biomarkers for bladder cancer (7, 8). Namely, inactivation of tumor suppressor genes TP53 and Rb and Ras oncogene activation have been considered as important key players in bladder cancer carcinogenesis (7).

MicroRNAs (miRNA; miR) are well known as examples of noncoding RNAs (9) and human miRNAs now number 1,100 based on microRNA.org (http://www.microrna.org/microrna/home.do). miRNAs bind to the 3'-untranslated region (UTR) of target gene mRNA and repress translation or induce mRNA cleavage (10), thereby inhibiting translation from mRNA to protein. Aberrant expression of miRNAs occurs in bladder cancer. Decreased expression of tumor suppressor miRNAs result in increased expression of target oncogenes. In contrast, increased expression of oncogenic miRNAs leads to loss or decreased expression of target tumor suppressor genes. According to previous reports, a number of miRNA microarray studies have been conducted in samples of patients with bladder cancer, and the expression level of several miRNAs (miR-17-5p, miR-23a, miR-23b, miR-26b, miR-103-1, miR-185, miR-203, miR-205, miR-221, and miR-223) were upregulated in bladder cancer tissues (11). In contrast, some miRNAs (miR-30-3p, miR-125, miR-133a, miR-145, miR-195, and miR-199a) were downregulated in bladder cancer compared with normal bladder tissues (12). miRNA expression level in paired primary and metastatic bladder cancers was validated using real-time PCR. The data show that the expression levels of several miRNAs (miR-10b, miR-29a, miR-29b, miR-126, miR-142-5p, miR-146a, miR-146b-5p, miR-150, miR-155, and miR-342-3p) were upregulated in...
miR-493 Targets RhoC and FZD4

metastatic bladder cancer tissues and some miRNAs (miR-143, miR-145, and miR-320) were downregulated (13); miR-129 was found to be upregulated in progressive bladder tumor and significantly associated with short survival (14). miR-125b was downregulated in bladder tumor tissues compared with normal bladder tissues, and overexpression of miR-125b inhibited cell growth in bladder cancer cell lines (15). However, there have been few reports about the detailed functional analysis of these miRNAs in bladder cancer.

The aim of this study was to identify new tumor suppressor miRNAs that influence bladder cancer progression. Initially, we conducted miRNA microarray analysis to screen miRNAs related to bladder cancer using normal bladder cells (SV-HUC-1) and 3 bladder cancer cell lines (J82, T24, TCCSUP). We identified 10 miRNAs whose expression level in bladder cancer cell lines was significantly higher or significantly lower than normal bladder cell line, SV-HUC-1. Next, we checked the microarray results by real-time PCR. Among 10 miRNAs, the expression of miR-493, miR-141, and miR-1290 was lower in bladder cancer cell lines and these results were consistent with the microarray data.

On the basis of microarray and real-time PCR results, we hypothesized that miR-493 may be a potential tumor suppressive miRNA in bladder cancer and found that miR-493 expression was significantly lower in bladder cancer tissues. Thus, we conducted functional assays using miR-493. Transfection of miR-493 into bladder cancer cells decreased cell growth, invasion, and migration. We also looked at potential target genes of miR-493 focusing on invasion and migration-related ones. We initially used a target scan algorithm (microRNA.org) to identify genes RhoC and FZD4 as targets of miR-493 and validated the results with a second target scan algorithm (TargetScan). We also conducted 3'-UTR luciferase assays and Western blot analysis to look at target gene protein expression in miR-493–transfected bladder cancer cells. Finally, we knocked down FZD4 and RhoC mRNAs using a short interfering RNA (siRNA) technique to examine and confirm the mechanism of miR-493 tumor suppressive function.

Materials and Methods

Cell lines and cell cultures
SV-HUC-1, T24, J82, and TCCSUP cells were purchased on February 2, 2010, from the American Type Culture Collection (ATCC). No authentication was done by the authors. T24, J82, and TCCSUP cells originating from transitional cell carcinoma were selected as model transitional cell carcinoma cells. SV-HUC-1 cells derived from normal uroepithelium were used as control cells. SV-HUC-1 cells were cultured in F-12K Medium (ATCC) with 10% FBS. T24 cells were cultured in McCoy’s 5A medium supplemented with 10% FBS. J82 cells were cultured in Minimum Essential Media (MEM) supplemented with 10% FBS. TCCSUP cells were cultured in MEM supplemented with 10% FBS, nonessential amino acids, and 1 mmol/L sodium pyruvate.

RNA extraction
The miRNA and total RNA were extracted from cell lines using a miRNeasy Mini Kit and an RNeasy Mini Kit (Qiagen). The miRNAs from clinical samples were extracted using laser capture microdissection techniques with a miRNeasy FFPE kit (Qiagen).

MicroRNA microarray
For miRNA microarray, total RNA was extracted from SV-HUC1, T24, J82, and TCCSUP cells using an miRNeasy Mini Kit. The miRNA microarray analysis was carried out and analyzed by Phalanx Bio Inc. We selected 10 miRNAs whose expression level in bladder cancer cell lines was significantly higher (top 5 miRNAs; miR-130b, miR-423-5p, miR-484, miR-503, miR-766) or significantly lower (top 5 miRNAs; miR-107, miR-141, miR-493, miR-933, miR-1290) than normal bladder SV-HUC-1 cells (Supplementary Table S1).

Tissue array samples
A human bladder cancer tissue array was purchased from US Biomax (catalog no.: BL801, US Biomax, Inc.) to detect miR-493 localization and confirm miR-493 expression levels in bladder cancer tissues by in situ hybridization. Tissue array patient information is shown in Supplementary Table S2.

Clinical samples
Twenty-three normal and 16 transitional cell carcinoma tissues in paraffin blocks were obtained from the Pathology Department of the Veterans Affairs Medical Center at San Francisco (San Francisco, CA). Informed consent was obtained from patients from the Veterans Affairs Medical Center at San Francisco.

Transfection
Pre-miR miRNA precursor (negative control/hsa-miR-493; Ambion), siRNA (control/RhoC/FZD4; Applied Biosystems, Invitrogen), Mock (without oligonucleotide), and cotransfection of Pre-miR miRNA precursor/pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega) were transiently transfected into cells by Lipofectamine 2000 (Invitrogen). Anti-miR miRNA inhibitors (negative control #1/has-miR-493; Applied Biosystems) were transiently transfected into cells by siPORT NeoFX Transfection Agent (Ambion).

Cell viability assay
Viability of T24 and J82 cells was measured by the MTS (CellTiter 96 Aqueous One Solution Cell Proliferation Assay; Promega) assay 4 days after transfection of Pre-miR miRNA precursor. Cell viability was determined by absorbance measurements at 490 nm using SpectraMax 190 (Molecular Devices). Data are presented as the mean value ± SD for triplicate experiments and compared with
the level of miR-493/siRNA obtained in mock or control miRNA/siRNA transfected cells that is normalized to 100%.

**Migration assay**
Transwell membrane filter inserts (8.0 mm pore size; BD Biosciences) were set in 24-well plate. T24 and J82 cells transfected with Pre-miR miRNA precursor or siRNA were harvested 72 hours after transfection and resuspended in serum-free MEM. Aliquots (5×10^4 cells/100 μL) of the prepared cell suspension were added into the upper chamber, and the lower chamber was filled with 1 mL of medium containing 10% FBS. Cells were incubated for 4 hours at 37°C in a 5% CO2 tissue culture incubator. After 4 hours, no migrated cells were removed from Transwell membrane filter inserts using cotton-tipped swab. migrated cells were stained with Hema 3 STAIN SET (Fisher Scientific). Cells per 3 random fields of each membranes were counted with Nikon ECLIPSE TS100 (Nikon) at ×100 magnification. Data are presented as the mean value ± SD for triplicate experiments and compared with the level of miR-493/siRNA obtained in mock or control miRNA/siRNA transfected cells that is normalized to 100%.

**Wound-healing assay**
T24 and J82 cells were seeded to 6-well plates and transfected with Pre-miR miRNA precursor or control. At 24 hours after transfection, cells were transferred from 6-well plates to 12-well plates. After 48 hours, a wound was formed by scraping the cells with a 200 μL pipette tip and washed twice with medium. We observed cells at 0, 24, and 72 hours after scraping and photographed the cells with a microscope (Nikon). Data are presented as the mean value ± SD for experiments and compared with the level of miR-493/siRNA obtained in mock or control miRNA/siRNA transfected cells that is normalized to 100%.

**Luciferase reporter assay**
A pmirGLO Dual-Luciferase miRNA target expression vector was used for 3'-UTR luciferase assays (Promega). The target oncogenes of tumor suppressor miRNA-493 were selected on the basis of target scan algorithms [microRNA.org (http://www.microrna.org/microrna/home.do) and TargetScan (http://www.targetscan.org)]. The primer sequences used are as follows: FhuC forward primer, 5'-AACTAGCGGCGCTAGCTTT CGGCCCTTTGACCTCTC-T3'; RhoC reverse primer, 5'-CTAGAGGAGCTCAGGGGCAAgTaCTAGCGGC CGCTAGTTT-T3'; FzD4 forward primer, 5'-AACTAG CGGCGCTAGCTTCA GTAACGGGCAAGTTTTAAGTGACCTCTC-T3'; FzD4 reverse primer, 5'-CTAGAGGAGCTCAGGGGCAAgTaCTAGCGGC CGCTAGTTT-T3'; mutant FzD4 forward primer, 5'-AACTAGCGGCGCTAGCTTT CGGCCCTTTGACCTCTC-T3'; mutant FzD4 reverse primer, 5'-CTAGAGGAGCTCAGGGGCAAgTaCTAGCGGC CGCTAGTTT-T3'; mutant FzD4 reverse primer, 5'-CTAGAGGAGCTCAGGGGCAAgTaCTAGCGGC CGCTAGTTT-T3'; mutant FzD4 reverse primer, 5'-CTAGAGGAGCTCAGGGGCAAgTaCTAGCGGC CGCTAGTTT-T3'. Mutant FzD4 reverse primer, 5'-CTAGAGGAGCTCAGGGGCAAgTaCTAG CGGCGCTAGCTTT CGGCCCTTTGACCTCTC-T3'; mutant FzD4 reverse primer, 5'-CTAGAGGAGCTCAGGGGCAAgTaCTAGCGGC CGCTAGTTT-T3';
anti-RhoA Antibody (#2117; Cell Signaling Technology),
FZD4 Antibody (#LS-C6904; LifeSpan BioSciences, Inc.),
and anti-β-actin (#3700; Cell Signaling Technology) antibodies. Western blot analysis was repeated independently 2 times.

**Immunoprecipitation**

At 72 hours after transfection, cells were washed in ice-cold PBS and added to cell lysis buffer (50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100) containing Protease Inhibitor Cocktail I (Millipore). Dishes were incubated for 5 minutes on ice, and cells were collected with a cell lifter and transferred to a 1.5-mL tube. Samples were sonicated on ice three times for 5 seconds followed by centrifugation at 14,000 × g for 10 minutes at 4°C. The supernatants were transferred to new 1.5-mL tubes. For cell lysate preclearing, protein G-agarose was added to sample tubes. Sample tubes were incubated at 4°C for 1 hour with gentle rocking followed by centrifugation at 14,000 × g for 10 minutes at 4°C. The supernatants were transferred to new 1.5-mL tubes. Anti-Rock-1 antibody (#ab45171; Abcam) or anti-control antibody (#2729; Cell Signaling Technology) was added to sample tubes, and these tubes were incubated with gentle rocking for overnight at 4°C. Protein G was added to sample tubes and these tubes were incubated with gentle rocking for 2 hours at 4°C followed by centrifugation at 14,000 × g for 30 seconds at 4°C. Samples were washed 5 times with cell lysis buffer. Sample buffer (2×) was added to sample tubes and vortexed followed by centrifugation at 14,000 × g for 1 minute. The supernatants were analyzed by Western blotting. Immunoprecipitation was repeated independently 2 times.

**In situ hybridization**

Tissue arrays were purchased from US Biomax, Inc. For in situ hybridization, IsHyb In Situ Hybridization (ISH) Kit was used according to the manufacturer’s instructions (BioChain). A tissue array slide was incubated overnight with a 1:500 dilution of miRCURY LNA Detection probe 5’-DIG labeled for miR-493 (EXIQON) and overnight at 4°C with a 1:200 dilution of AP-conjugated anti-digoxigenin antibody. BM Purple; AP substrate precipitating, (NBT/BCIP ready-to-use solution; Roche) was used as detector. Staining intensity of in situ hybridization was divided into 0, no staining; 1, positive staining; and 2, strong positive staining.

**siRNA knockdown of RhoC and FZD4 mRNA**

T24 and J82 cells were transfected with RhoC and FZD4 siRNA (RhoC Silencer Select Validated siRNA, siRNA ID s97 and FZD4 Silencer Select Validated siRNA, siRNA ID s15840; Applied Biosystems), RhoC and FZD4 siRNA (RHOC Stealth RNAi siRNA HSS100662 and FZD4 Stealth RNAi siRNA HSS188730; Invitrogen) or negative control siRNA using Lipofectamine 2000 according to the manufacturer’s instructions.

**Statistical analysis**

All statistical analyses were conducted using GraphPad prism 5 software (GraphPad Software). A value of \( P < 0.05 \) was considered as statistically significant.

**Results**

**Expression level of miR-493 in cell lines and primary tissues**

To identify tumor suppressor miRNAs in bladder cancer, we conducted an miR microarray using SV-HUC-1 as a normal bladder cell line and 3 bladder

![Figure 1. Expression level of 10 miRNAs in bladder normal and cancer cell lines. Ten miRNAs were selected on the basis of miRNA microarray data (Phalanx Bio Inc). Low, miRNA expression is significantly lower in bladder cancer cell lines than in normal cell line (SV-HUC-1) based on miRNA microarray data. High, miRNA expression is significantly higher in bladder cancer cell lines than in normal cell line (SV-HUC-1) based on miRNA microarray data. The 10 miRNA expression levels in SV-HUC-1 and bladder cancer cell lines were also measured by real-time PCR and normalized to RNU48. Data are presented as mean value ± SD for 3 independent experiments and compared with the level in SV-HUC-1 cells normalized as 1.](mct.aacrjournals.org)
cancer cell lines, T24, J82, and TCCSUP, and selected 10 miRNAs for our study (Supplementary Table S1). Namely, the expression of 5 miRNAs was significantly higher (top 5) and that of 5 miRNAs were significantly lower (top 5) in bladder cancer cell lines than in normal bladder cells. To confirm the expression of these 10 miRNAs, we carried out real-time PCR and found that miR-107, miR-141, miR-493, and miR-1290 expression in bladder cancer cells was significantly lower than that in SV-HUC-1 (P < 0.0001; Figs. 1 and 2A). miR-933 expression was not detected in bladder cell lines using real-time PCR. The real-time PCR data showed similar results as the microarray data for miR-107, miR-141, miR-493, miR-503, and miR-1290, whereas some miRs showed opposite results (miR-130b, miR-423-5p, miR-484, and miR-766) as the expression was higher than in SV-HUC-1.

Localization of miR-493 expression and decreased miRNA-493 expression in bladder cancer tissues
To investigate miR-493 localization in human bladder tissues, we carried out in situ hybridization in bladder tissue array (normal and cancer tissues). As shown in Fig. 2B, miR-493 expression was significantly lower in bladder cancer tissues than in normal bladder tissues (P = 0.0416). Expression of miR-493 was observed in connective tissues, endothelial cells of blood vessels, and lamina muscularis mucosa in normal bladder tissues (data not shown). In urothelial cell carcinoma, miR-493 expression was lower than in layers of normal urothelium (Supplementary Fig. S1). We then compared miRNA-493 expression levels in bladder cancer tissues and normal bladder tissues by real-time PCR to validate the ISH results. Similar to the ISH results, the expression of miR-493 was significantly lower in bladder cancer tissues than in normal bladder tissues. The expression of miR-493 in the normal bladder cell line, SV-HUC-1, was used as reference (expression = 1). Consistent with the ISH results, the miR-493 expression was significantly lower in bladder cancer tissues (P = 0.0080) than in normal tissues (Fig. 2C). Regarding miR-107, miR-141, and miR-1290, we did not find any difference of expression between normal bladder tissues and bladder cancer tissues (Supplementary Fig. S2).

Evaluation of the functional effects of miR-493 on T24 and J82 cells
As the expression of miR-493 was significantly lower in bladder cancer cell lines and bladder cancer tissues than in normal bladder cell lines and tissues, we next focused on the functional effects of miR-493 on bladder cancer cells. miR-493 and miR control were transiently transfected into T24 and J82 cells. The expression level of miR-493 was significantly increased at 48 hours after transfection (Fig. 3A). Cell viability was decreased to 70% to 80% in miR-493-transfected cells compared with controls at 4 days after transfection (P = 0.0286; Fig. 3B). Cell motility was also significantly decreased in miR-493-transfected T24 and J82 cells (P = 0.0068 and P < 0.0001, respectively, Fig. 3C).
miR-493 Targets RhoC and FZD4

Identification of miR-493 target genes and its effect on their 3'-UTR-luciferase assays and protein expression

On the basis of the observation that miR-493 affects cell motility and migration, we searched for target genes of miR-493 related to motility and migration using a target scan algorithm (microRNA.org; http://www.microrna.org/microrna/home.do) and identified RhoC and FZD4 as target oncogenes. As shown in Fig. 4A, FZD4 mRNA has one potential complimentary miR-493–binding site within its 3'-UTR. RhoC mRNA also has one potential complimentary miR-493–binding site within its 3'-UTR. We conducted RhoC and FZD4 3'-UTR luciferase assays and found that the relative luciferase activities with these sites were significantly decreased in miR-493–transfected T24 cells (P = 0.0004 and P = 0.0007, respectively; Fig. 4B). With mutated plasmids, there was no significant difference in luciferase activity between controls and mutated miR-493 transfectants. To examine the inhibitory effect of miR-493 on protein expression levels, we conducted Western blot analysis 72 hours after miR-493 transfection into T24 and J82 cells. We observed that the protein levels of RhoC and FZD4 in miR-493–transfected T24 and J82 cells were significantly decreased compared with control cells;
of RhoC and FZD4 protein expression was also confirmed by Western blot analysis (Fig. 5A and B). To determine whether RhoC and FZD4 knockdown affects cell migration, migration assay was conducted using T24 and J82 cells. Cell migration was significantly decreased to 35% to 50% in si-RhoC and si-FZD4 transfectants compared with control cells (P = 0.0015 and P = 0.0064, respectively; Fig. 5C and P = 0.0010 and P = 0.0007, respectively; Fig. 5D). To examine potential off-target effects of siRNA, other RhoC and FZD4 siRNAs from a different source were also used (Supplementary Fig. S5). As shown in Supplementary Fig. S5, the results were consistent with Fig. 5. These data suggest that the siRNAs used in this study did not induced the off-target effects in the siRNA experiments.

**Effect of miR-493 on the binding of RhoC to Rock-1 in bladder cancer cells**

To analyze whether overexpression of miR-493 affects the binding of RhoC to Rock-1, immunoprecipitation was carried out at 72 hours after transfection in T24 cells. We found that the binding of RhoC to Rock-1 in miR-493–transfected T24 cells was decreased compared with miR control transfectants (Fig. 6A). We also analyzed the binding of RhoC to Rock-1 after FZD4 siRNA transfection. At 72 hours after transfection, the binding was decreased in siFZD4-transfected cells (Fig. 6B). The schematic representation of the possible role of miR-493 in the FZD4/RhoC signaling pathway is shown in Fig. 6C.

**Discussion**

There have been several miRNA studies related to clinical bladder cancer and most have involved microarray screening (11–15). We used an miR microarray service to compare miRNA expression levels in a normal uroepithelium cell line (SV-HUC-1) and bladder cancer cell lines (T24, J82, and TCCSUP). On the basis of the miRNA microarray data, we initially chose 10 miRNAs whose expression was significantly higher (5 miRNAs) or lower (5 miRNAs) than the normal bladder cell line. Among the 10 miRNAs, the expression of miR-493 and miR-141 was lower in bladder cancer cell lines than in the normal cell line which is consistent with previous miRNA microarray results; however, there are no reports concerning the functional role of miR-493 in bladder cancer.

Thus, we focused on miR-493 as a potentially new candidate tumor suppressor miRNA in bladder cancer. In addition, we confirmed the miR-493 expression level in clinical bladder cancer tissues using ISH and real-time PCR. The expression of miR-493 was significantly lower in clinical bladder cancer tissues than in normal bladder tissues. On the basis of these results, we hypothesized that miR-493 may play an important role as a tumor suppressor in bladder cancer. To test this hypothesis, we conducted functional analyses (MTS, migration, wound healing, and cell cycle) to look at miR-493 function using miR-493–transfected cells. As expected, miR-493 overexpression inhibited cell proliferation in bladder cancer cells (T24 and J82). Cell migration and motility were also dramatically increased in siFZD4-transfected cells (Fig. 6C). Therefore, we hypothesized that the FZD4/RhoC signaling pathway may play a role in bladder cancer development and progression.
decreased after miR-493 transfection. These results suggest that miR-493 may function as a tumor suppressor and play an important role in inhibition of cell growth and motility of bladder cancer cells.

As a next step, we also used microRNA.org to identify target oncogenes of miR-493 and identified potential candidate target oncogenes related to invasion and migration. TargetScan also showed $RhoC$ and $FZD4$ as miR-493 target genes (Supplementary Fig. S6). We conducted 3′-UTR luciferase assay and observed that luciferase activity was decreased after cotransfection of miR-493 and a 3′-UTR vector containing the $RhoC$/FZD4 miR-493 target sequence. RhoC and FZD4 protein expression were also significantly downregulated in miR-493–transfected T24 and J82 cells indicating that RhoC and FZD4 are direct targets of miR-493.

It has been reported that RhoC protein is overexpressed in bladder tumor tissues compared with bladder nontumor tissues and higher RhoC protein expression in tumors was associated with clinicopathologic factors (grade and pT), with poorer disease-free survival and overall survival than low expression (17). Although there have been no reports about RhoC function in bladder cancer, in hepatocellular carcinoma cells, RhoC is essential for invasion and migration but not proliferation and apoptosis (18). This is consistent with our finding that cell migration in
T24 and J82 RhoC knockdown was significantly decreased compared with control siRNA. However, cell growth in T24 and J82 RhoC knockdowns was not significantly different compared with control siRNA (data not shown). This cell growth inhibition result is consistent with RhoC function in hepatocellular carcinoma cells (18). It has been reported that RhoC is essential for invasion in some cancers (19–24), and RhoC expression is significantly correlated with poor prognosis (25–27). FZD4 knockdown decreased the binding of RhoC to Rock-1. We have also previously reported that miR-584 targets Rock-1 (16). As high Rock-1 expression in bladder tumors was associated with poor disease-free survival and overall survival than low expression (17), functional RhoC and Rock-1 in bladder cancer may be important to malignancy progression.

It has also been reported that miR-138 directly targets RhoC and Rock-2 in tongue squamous cell carcinoma and inhibits cell migration and invasion (28). Our microarray data show that miR-138 expression in TCCUP cells is significantly lower than in SV-HUC-1, but not in T24 and J82 cells (Supplementary Table S1).

Our study showed that miR-493 inhibited FZD4 and RhoC and this pathway is involved in Wnt-PCP pathway. Wnt signaling pathways include the following: (i) Wnt-β-catenin, (ii) Wnt-PCP, and (iii) Wnt-Ca²⁺, and these signaling pathways have been reported to be associated with cancer progression and poor prognosis (29). In bladder cancer, Ras oncogene activation plays a very important role in bladder cancer progression (7). Interestingly, Ahmad and colleagues have recently reported that Ras pathway activation cooperates with Wnt-β-catenin signaling to drive urothelial cell carcinoma (30). There are few reports about other Wnt signaling pathways (Wnt-PCP or Wnt-Ca²⁺) in bladder cancer. In conclusion, our study suggests that miR-493 may be a new tumor suppressive miRNA inhibiting cell invasion and migration by blocking FZD4 and RhoC in bladder cancer, implicating the Wnt-PCP pathway in bladder carcinogenesis.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Dr. Roger Erickson for his support and assistance with the preparation of the manuscript.

Grant Support

This study was supported by grants R01CA130860, R01CA138642, R01CA111470, T32DK007790 from the NIH, VA Research Enhancement Award Program (REAP), and Merit Review grants. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 3, 2011; revised October 24, 2011; accepted October 29, 2011; published OnlineFirst November 4, 2011.

References

miR-493 Targets RhoC and FZD4


Molecular Cancer Therapeutics

Tumor Suppressor MicroRNA-493 Decreases Cell Motility and Migration Ability in Human Bladder Cancer Cells by Downregulating RhoC and FZD4


Mol Cancer Ther 2012;11:244-253. Published OnlineFirst November 4, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-11-0592

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2011/11/02/1535-7163.MCT-11-0592.DC1

Cited articles
This article cites 30 articles, 7 of which you can access for free at:
http://mct.aacrjournals.org/content/11/1/244.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/11/1/244.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.